BACKGROUND the association of aldosterone with the metabolic syndrome (Mets) has not been fully elucidated. the aim of our study was to evaluate the relationships of plasma aldosterone concentration (pAC) with Mets and left ventricular mass (LVM) in nondiabetic Caucasian patients with essential hypertension.
The metabolic syndrome (MetS) carries an increased risk of cardiovascular (CV) diseases in the general population 1 and also in subjects with high blood pressure (BP), [2] [3] [4] even in the absence of diabetes. 2, 4 Several lines of evidence suggest that this enhanced CV risk may partially be mediated by the increased prevalence of subclinical organ damage, such as left ventricular (LV) hypertrophy, as is observed in individuals with MetS. [5] [6] [7] [8] The mechanisms responsible for this increased occurrence of preclinical CV changes in subjects with MetS are only in part known. 5 A growing body of evidence links excess of aldosterone to CV remodeling and injury in several pathological conditions. 9 The association of aldosterone with MetS remains to be fully elucidated, especially in Caucasian subjects.
The aim of our study was to evaluate the relationship of plasma aldosterone to MetS and to LV mass (LVM) in nondiabetic white patients with essential hypertension.
METHODS
The study population was selected from 587 hypertensive consecutive patients attending our hypertension center. Eighty of these patients were not enrolled because of secondary or malignant hypertension, heart failure, positive history or clinical signs of ischemic heart disease, cerebrovascular disease, renal insufficiency (estimated creatinine clearance < 60/ml/ min/1.73 m 2 ), overt proteinuria, major non-CV diseases, or known diabetes or fasting glycemia ≥126 mg/dl.
Primary aldosteronism was excluded on the basis of an aldosterone/renin ratio >40. For the calculation of the aldosterone/ renin ratio the plasma renin activity (PRA) values <0.2 ng/ml/h were arbitrarily set to 0.2, in line with the PAPY (Primary Aldosteronism Prevalence in Hypertensives) study. 10 Before being enrolled in the study, 259 of the subjects had been pharmacologically treated for hypertension. In all these patients treatment was withdrawn for at least 2 weeks before commencing the study. No subject was taking aldosterone antagonists. Twelve individuals whose BP increased to >180/110 mm Hg during the washout period were not enrolled.
Only nine patients (six with and three without MetS) had been treated with lipid-lowering agents (statins or fibrates) prior to enrolment. For various reasons these therapies were discontinued at least 1 month before entering the study.
Of the remaining hypertensive patients, 45 were excluded because of suboptimal echocardiographic tracings or technically substandard 24-h ambulatory BP monitoring. Therefore the final statistical analysis involved 450 patients.
All these patients had clinic systolic BP values ≥140 mm Hg and/or clinic diastolic BP values ≥90 mm Hg, except 40 previously pharmacologically treated subjects (22 with and 18 without MetS) in whom BP values at the end of the washout period were below 140/90 mm Hg, but above 130/85 mm Hg.
Written informed consent was obtained from each patient. The study protocol, conforming to the ethical guidelines of the Declaration of Helsinki, was approved by the local review board.
Study design. For all the subjects a careful clinical history was recorded and physical examination was carried out. After the period of pharmacological washout, body weight, height, and waist circumference were measured by a nurse, and clinic BP was recorded in the seated posture by a doctor. The clinic BP was taken as the average of three consecutive measurements obtained using a mercury sphygmomanometer, after the patient had rested for 5 min.
An echocardiographic study and a 24-h ambulatory BP monitoring were also carried out. Additionally, a 24-h urine sample was collected to evaluate electrolyte excretion. The adequacy of the 24-h urine collection was assessed by measuring 24-h urinary creatinine output, and this value in all the participants was 1,681 ± 747 mg/day. The following morning, after an overnight fast of at least 10 h and after 1 h in the supine position, blood samples were drawn to perform routine blood chemistry and to assay PRA and PAC.
All the subjects were instructed to ingest a diet containing 130-140 mmol/day sodium and 40-50 mmol/day potassium for 2 weeks before the biochemical evaluation.
Measurements. Routine biochemical parameters were determined with standard techniques, using an autoanalyzer (Hitachi system 911; Boehringer Mannheim, Mannheim, Germany). Low-density lipoprotein cholesterol was calculated using the Friedwald formula.
PRA and PAC were measured by radioimmunoassay 11 using commercially available kits (RENCTK for the former and ALDCTK-2 for the latter), both purchased from Sorin Biomedica Diagnostics (Saluggia, Italy).
PRA was determined as angiotensin-I generation rate, in accordance with the method described by Sealey and Laragh, 11, 12 and expressed as nanograms of angiotensin-I formed per milliliter of plasma per hour of incubation (ng/ml/h).
Within-assay and between-assay coefficients of variation of the method for determination of PAC were 5.3 and 7%, respectively.
As detailed in the National Cholesterol Education ProgramAdult Treatment Panel III report, recently slightly revised by an American Heart Association/National Heart, Lung, and Blood Institute scientific statement, 1 MetS was defined by the presence, in addition to hypertension, of two or more of the following criteria: high-density lipoprotein <40 mg/dl in men or 50 mg/dl in women; fasting glucose between 100 and 125 mg/dl; triglycerides >150 mg/dl; and waist circumference >102 cm in men and >88 cm in women.
A portable, noninvasive SpaceLabs 90207 recorder (SpaceLabs, Redmond, WA) was used for performing the 24-h ambulatory BP monitoring. Only records with >80% of valid data were accepted.
M-mode echocardiography guided by two-dimensional echocardiography was performed, in line with the American Society of Echocardiography recommendations. 13 The procedure was performed by a single cardiologist who was blinded as to the patient's clinical characteristics, using an Acuson Sequoia 512 (Siemens, Mountain View, CA).
Myocardial relative wall thickness was calculated as two times the thickness of the posterior wall in diastole divided by internal diameter, and was used as an estimate of LV geometry. LVM was determined using the ASE-corrected cube formula. 14 It was indexed by height elevated to the power of 2.7 (LVMH 2.7 ), as suggested by de Simone et al., 15 in order to provide a more stringent allowance for obesity.
In our laboratory, the mean intra-observer variability for LVM was 8.6%. LV hypertrophy was defined as LVMH 2.7 ≥50 g/m 2.7 for men and ≥47 g/m 2.7 for women, which are the values representing the upper limits of normal sex-specific 95% confidence intervals in reference populations. 15 Statistics. The study was planned to have a sample size in the MetS group of ≥195 participants. This figure was calculated on the basis of a previous investigation that explored a similar issue, 16 hypothesizing the finding of a coefficient of correlation between PAC and LVMI of at least 0.20 and a difference regarding aldosterone levels of at least 1 ng/dl between subjects with and without MetS, assuming a standard deviation of 6 ng/dl. On this basis, it was estimated that the study would have >80% power to detect the expected results (with α = 0.05).
Normal distribution of the continuous variables was assessed using the Kolmogorov-Smirnov test and the assumption of satisfactory normal distribution was met for all of the examined variables, except for PAC and PRA, which showed a positively skewed distribution. Because the application of nonparametric tests to these variables or their mathematical transformations provided similar results to those obtained using parametric tests or untransformed data, we have used only the latter in this paper. Continuous variables are shown as mean values ± s.d.
Differences between groups with and without MetS were evaluated using the independent-sample Student's t-test for continuous variables and the χ 2 -test, with Yates' correction for the categorical variables. Adjustment for age and other potential confounders was carried out by analysis of covariance. Univariate associations between PAC and LVM, and of these parameters with other variables, were assessed using Pearson correlation coefficients. Backward, stepwise multiple linear regression analyses were used to assess the independent correlates of PAC, using aldosterone as dependent variable, and age, sex, PRA, serum (or urinary) potassium level, previous pharmacological therapy, and the MetS (coded as 1 for presence and 0 for absence) as explanatory variables. Subsequently, the model was run again with the addition of the single components of MetS associated with PAC in univariate analysis, in order of the strength of correlation: waist circumference (or body mass index (BMI)), clinic BPs and high-density lipoprotein cholesterol.
Another multiple regression analysis was performed to test the independent relationships between PAC and LVM in multivariate models with LVMH 2.7 as dependent variable, the covariates being age, gender, PRA, duration of hypertension, previous antihypertensive treatment, 24-h (or clinic) systolic and diastolic BPs, BMI (or waist circumference), glycemia, triglycerides and highdensity lipoprotein cholesterol. This model was run in the whole study population and in the two groups with and without MetS (model 1). Subsequently we ran a second model including only the variables that had shown a statistically significant association with LVMH 2.7 in model 1, along with MetS in the whole study population (model 2) and with PAC in the two subgroups (model 2a). Finally, we built a third model (model 3) in the overall population by adding PAC and the interaction term "MetS × PAC, " to assess whether the two groups were different with regard to the association between LVM and PAC.
A two-tailed P < 0.05 was considered statistically significant. The statistical analyses were performed using the SYSTAT DATA software package, version 12 (Systat, San Jose, CA). Table 1 gives some of the clinical and demographic characteristics of all the subjects included in the study and of the groups into which the study population was divided in line with the National Cholesterol Education Program-Adult Treatment Panel III definition of MetS.
RESULTS
The prevalence of MetS in the hypertensive population in our study was 44.7% (201/450). Patients with MetS were older, had experienced a longer duration of hypertension and had higher levels of total cholesterol. In the group with MetS, it was observed that there was a higher percentage of patients who had received pharmacological treatment earlier for hypertension. Among the subjects in whom antihypertensive drugs had been suspended, the earlier treatment regimens were similarly distributed between those with MetS and those without: angiotensin-converting enzyme inhibitors (alone or in combination with a diuretic) (35% vs. 34%), angiotensin II receptor blockers (alone or in combination with a diuretic) (23% vs. 27%), β-blockers or α-β-blockers (alone and in combination with a diuretic) (11% vs. 15%), calcium antagonists (15% vs. 12%), α-blockers (2% vs. 1%), a combination of two or more of these drugs (14% vs. 11%) (all P > 0.5). The overall percentage of patients treated with diuretics was not different in the two groups (47% vs. 43%, P = 0.57). Similar results were replicated also in the subset of nevertreated hypertensive patients (95 with and 178 without MetS). Indeed, whereas age-adjusted PRA did not differ in the two groups (0.59 ± 0.58 vs. 0.51 ± 0.53 ng/ml/h; P = 0.25), ageadjusted PAC was higher in subjects with MetS than in those without (12.2 ± 6.2 vs. 10.5 ± 6.1 ng/dl; P = 0.03). The same was true for the unadjusted values of PAC (12.1 ± 6.1 vs. 10.4 ± 6.1 ng/dl; P = 0.03).
As presented in Table 2 , clinic and 24-h systolic BPs were higher in participants with MetS than in those without. A similar pattern was observed for end-diastolic LV internal dimension, posterior wall thickness, interventricular septum thickness and LVM. The prevalence of LV hypertrophy was also significantly greater in the group of hypertensive individuals with MetS in comparison than in those without ( Table 2 ). All these difference regarding BP values and cardiac parameters held even after adjusting for age by analysis of covariance (all P ≤ 0.01).
The univariate correlations of PAC with other variables in the overall study population and in the groups with and without MetS are displayed in Table 3 .
When we assessed, in the whole study population, the independent correlates of PAC in a multiple regression model including PAC as dependent variable, and age, gender, serum potassium level, previous pharmacological therapy, PRA and MetS as covariates, only PRA (β = 0.26; P < 0.0001), and MetS (β = 0.12; P = 0.01) remained significantly associated with PAC. The inclusion into the model of urinary, instead of serum, potassium level did not modify the results. However, the association between MetS and PAC lost statistical significance (P ≥ 0.48) when we added waist circumference (or BMI) to the multivariate model. After further adjustment for highdensity lipoprotein cholesterol and clinic BPs, the standardized regression coefficients relating waist circumference with PAC and BMI with PAC, were both 0.14; P = 0.002.
PAC correlated positively and significantly with LVMH 2.7 in the whole study population and in subjects with and in those without MetS (Figure 1 and Table 3) .
Similar results were obtained also in the subset of nevertreated hypertensive patients in whom the coefficients of correlation were highly significant, especially in the MetS group (r = 0.28; P = 0.005 for the correlation between PAC and LVMH 2.7 ).
In the overall population, after adjusting for potential confounders, LVMH 2.7 was associated with MetS as a whole and with BMI ( Table 4 ). The latter, but not the former, relationship was attenuated, but still significant after further adjustment for PAC (model 3, Table 4 ). In the group with MetS, the association of LVMH 2.7 with PAC remained statistically significant in multivariate analyses. In the group without MetS, the same relationship became of borderline statistical significance ( Table 4) .
These results did not significantly change when 24-h BPs were replaced with clinic BPs and BMI was replaced with waist circumference in the multivariate models.
DISCUSSION
This study shows that plasma aldosterone levels are higher in nondiabetic Caucasian essential hypertension subjects with MetS as compared to those without MetS. The difference in respect of PAC was independent of age and PRA, and was detected also in a subset of hypertensive individuals who had never been pharmacologically treated for high BP. However, we found that MetS per se is not associated with PAC, and that the observed association is chiefly attributable to one of the key individual components of MetS, which is obesity. This was clear from the finding that it lost statistical significance after adjustment in multivariate analysis for waist circumference or BMI.
The association of PAC with a clustering of metabolic CV risk factors was reported for the first time by Egan in 1994 in a group of 29 volunteers of unidentified ethnicity. 17 Table 3 In a more recent study performed in the Seychelles, populated predominantly by people of East African descent, PRA and PAC were found to be associated with different components of MetS, but only aldosterone was associated with MetS per se, even after adjustment for its separate components. 18 An independent relationship between PAC and MetS was also observed by Kidambi et al. in a sample of 397 African-American subjects. 19 In that study a relationship between aldosterone and waist circumference was also found. 19 The association of aldosterone with MetS has not been fully elucidated in Caucasian individuals.
In a subanalysis of the TROPHY (Trial of Preventing Hypertension) study, enrolling mostly white volunteers with high-normal BP, no evidence of elevated aldosterone or PRA was found in subjects with MetS when compared with controls without MetS. 20 Some differences between the characteristics of the participants in our study and those of the TROPHY study 20 (hypertensive patients in our study and subjects with high-normal BP in the TROPHY trial; a lower BMI, a younger age and a greater number of subjects enrolled in our study than in the TROPHY trial) could potentially explain the discrepancies in the results of the two investigations.
In the Framingham Offspring Study, predominantly comprising white participants, higher circulating aldosterone levels were shown to predispose persons to the subsequent development of MetS. 21 This finding suggests that aldosterone elevation predates and may cause MetS. This is in part supported by clinical trials demonstrating that blockers of the renin-angiotensin-aldosterone system decrease the risk of future diabetes. 22 However, on the basis of the available evidence, [23] [24] [25] [26] [27] it is also possible to hypothesize an inverse causal relationship. For example, some components of MetS, such as visceral obesity, may induce an increased production of aldosterone. 26, 27 This hypothesis was not formally tested in the Framingham Offspring Study. 21 Consistent with previous reports, 16, 19, [23] [24] [25] we found a close relationship between obesity and plasma aldosterone, being PAC positively correlated with both BMI and waist circumference, and this correlation was the main explanation of the association between PAC and MetS. These results seem to be biologically plausible, because several mechanisms may explain how aldosterone is potentially linked to obesity and to MetS.
Indeed, it has been demonstrated that a variety of adipose tissue-derived factors can stimulate aldosterone synthesis. Goodfriend et al. 26 reported that an epoxy-keto derivative of linoleic acid (EKODE), one of the oxidized products of fatty acids, stimulates aldosterone secretion in rat adrenal cells.
More recently, in vitro experiments documented that human adipocytes secrete potent mineralcorticoid releasing factors, not yet well identified. 27 On the other hand, the low levels of plasma natriuretic peptides observed in individuals with obesity and MetS 28 might predispose to increased adrenal production of aldosterone, because the stimulatory effect of EKODE on aldosteronogenesis is inhibited by atrial natriuretic peptide. 26 Moreover, insulin resistance and the accompanying compensatory hyperinsulinemia, which are regarded as the pathophysiological key features underlying visceral obesity and MetS, may contribute toward increasing PAC, because insulin is known to stimulate aldosterone synthesis in vitro; 29 reciprocal relationships between aldosterone, insulin resistance and hyperinsulinemia have been described in clinical and experimental studies. 19, 23, 25, [30] [31] [32] Other important results of our study are worth noting. In agreement with previous reports, 5, 6, 8 patients with MetS exhibited increased values of LVM, which were closely related to plasma aldosterone levels. However, even though in the overall study population LVMH 2.7 was independently associated with MetS as a whole and with BMI, only the latter relationship was attenuated after further adjustment for PAC in multivariate analyses. This suggests that the relationship between PAC and LVMH 2.7 in the MetS is mediated mainly by obesity.
Several lines of evidence suggest a key role for aldosterone in LV remodeling. 9 However, although there is sound evidence that primary aldosteronism is associated with LV hypertrophy, 9,33 it is not clear whether aldosterone plays an independent role in the development of LV hypertrophy in patients with essential hypertension. Several studies that sought to explore this issue in the past yielded inconsistent results. 16, [34] [35] [36] [37] [38] Some of these investigations were limited by small samples or incomplete adjustment for confounders.
Our findings seem to suggest that in essential hypertensive patients PAC may contribute to increase LVM independently of its impact on systemic BP. Though no significant interaction was found between MetS and PAC in respect of the relationship between PAC and LVM, it is worth noting that in the group of subjects with MetS, the association of PAC with LVMH 2.7 persisted even after adjusting for age, gender, BMI, duration of hypertension, previous antihypertensive treatment, 24 -h systolic and diastolic BPs, and PRA. When we repeated the multivariate analysis in the group without MetS, the association of PAC with LVM became of borderline statistical significance.
Some limitations of our study should be noted. The crosssectional nature of the study does not allow us to establish the direction of causality relations between PAC, MetS, and LVM. Moreover, given the well-known interactions between cortisol, aldosterone, and the mineralcorticoid receptors, 9 and in view of the acute stimulatory effects of ACTH on adrenal aldosterone production, 9 the lack of data about cortisol and ACTH plasma levels may be another possible limitation.
An additional limitation is that we did not assess LV diastolic function, which may be impaired by aldosterone, given its known stimulatory effects on cardiac collagen synthesis and fibroblast proliferation under experimental conditions. 9 In conclusion, PAC values are higher in nondiabetic white hypertensive patients with MetS than in those without, a difference that is mainly related to obesity. These elevated levels of aldosterone may help to explain the increased LVM observed in subjects with MetS and may thereby contribute toward enhancing the CV risk associated with MetS. Although there is need for caution in interpreting the results because of the cross-sectional design of this study, our results suggest that, in addition to lifestyle interventions directed toward reducing articles Aldosterone, Metabolic Syndrome, and LV Mass body weight, treatment with aldosterone antagonists may have potential beneficial effects in hypertensive subjects with MetS. Additional studies are needed to test this hypothesis.
